Precision BioSciences (DTIL) Hits New 12-Month Low at $13.53

Shares of Precision BioSciences (NASDAQ:DTIL) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $13.53 and last traded at $13.71, with a volume of 2349 shares changing hands. The stock had previously closed at $14.60.

In other news, Director Tony Dung Ling Yao acquired 6,487 shares of Precision BioSciences stock in a transaction dated Wednesday, April 3rd. The stock was bought at an average price of $15.42 per share, for a total transaction of $100,029.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Global Strategic Fund Venbio acquired 50,000 shares of Precision BioSciences stock in a transaction dated Monday, April 1st. The shares were purchased at an average price of $16.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.wkrb13.com/2019/04/11/precision-biosciences-dtil-hits-new-12-month-low-at-13-53.html.

About Precision BioSciences (NASDAQ:DTIL)

Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.

Further Reading: What are no-load funds?

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.